|
[1]ELLIS EL, MANN DA.Clinical evidence for the regression of liver fibrosis[J].J Hepatol, 2012, 56 (5) :1171-1180.[2]SHEN YY, TANG QJ.Clinical efficacy of compound Chinese medicine preparation in treating liver fibrosis among patients with hepatitis B[J].J Changchun Univ Tradit Chin Med, 2011, 27 (3) :421-422. (in Chinese) 沈英宇, 唐秋君.中药复方制剂治疗乙肝后肝纤维化临床观察[J].长春中医药大学学报, 2011, 27 (3) :421-422.[3]XIE JR, LIU Y, LIANG GY, et al.Effects of Rouganjian decoctin on liver function and serum liver fibrosis in patients with liver fibrosis induced by chronic hepatitis B[J].Jilin Tradit Chin Med, 2012, 32 (7) :688-689. (in Chinese) 谢晶日, 刘洋, 梁国英, 等.柔肝煎对慢性乙型肝炎肝纤维化患者肝功能及血清肝纤维化指标的影响[J].吉林中医药, 2012, 32 (7) :688-689.[4]POELSTRA K, SCHUPPAN D.Targeted therapy of liver fibrosis/cirrhosis and its complications[J].J Hepatol, 2011, 55 (3) :726-728.[5]LI J, FAN R, ZHAO S, et al.Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells[J].Int J Mol Sci, 2011, 12 (4) :2434-2447.[6]KMIEC'Z.Cooperation of liver cells in health and disease[J].Adv Anat Embryol Cell Biol, 2001, 161:III-XIII, 1-151.[7]ROWE IA, GALSINH SK, WILSON GK, et al.Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication[J].Hepatology, 2013, Jun 14.[Epub ahead of print][8]HONDA E, PARK A, YOSHIDA K, et al.Myofibroblasts:biochemical and proteomic approaches to fibrosis[J].Tohoku J Exp Med, 2013, 230 (2) :67-73.[9]TAGUCHI K, FUJIKAWA N, KOMATSU M, et al.Keap1 degradation by autophagy for the maintenance of redox homeostasis[J].Proc Natl Acad Sci U S A, 2012, 109 (34) :13561-13566.[10]SZABO G, BALA S.MicroRNAs in liver disease[J].Nat Rev Gastroenterol Hepatol, 2013.[Epub ahead of print][11]HE Y, HUANG C, LIN X, et al.MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J].Biochimie, 2013, 95 (7) :1355-1359.[12]JOPLING C.Liver-specific microRNA-122:Biogenesis and function[J].RNA Biol, 2012, 9 (2) :137-142.[13]VETTORI S, Gay S, Distler O.Role of MicroRNAs in Fibrosis[J].Open Rheumatol J, 2012, 6 (Suppl 1:M9) :130-139.[14]LI Q, YAN Z, LI F, et al.The improving effects on hepatic fibrosis of interferon-γliposomes targeted to hepatic stellate cells[J].Nanotechnology, 2012, 23 (26) :265101.[15]REETZ J, GENZ B, MEIER C, et al.Development of adenoviral delivery systems to target hepatic stellate cells in vivo[J].PLoS One, 2013, 8 (6) :e67091.[16]CHEN PS, LIU F, DING FG, et al.Inhibition of liver fibrosis in vitro using vitamin A-coupled liposomes to deliver MMP-2 siRNA[OL].Sciencepaper Online, http://www.paper.edu.cn/index.php/default/releasepaper/content/201212-502. (in Chinese) 陈平圣, 刘凤, 丁粉干, 等.VitA偶联脂质体包裹MMP-2 siRNA靶向预防肝纤维化的体外研究[OL].[2012-12-20].中国科技论文在线, http://www.paper.edu.cn/releasepaper/content/201212-502.[17]YAMADA Y, HASHIDA M, HAYASHI Y, et al.An approach to transgene expression in liver endothelial cells using a liposomebased gene vector coated with hyaluronic acid[J].J Pharm Sci, 2013, 102 (9) :3119-3127.[18]WANG W, YUAN Z.Recent development of liver targeted drug delivery system based on nanotechnology[J].Polymer Bulletin, 2013, 25 (1) :137-154. (in Chinese) 王蔚, 袁直.肝靶向纳米给药系统的最新研究进展[J].高分子通报, 2013, 25 (1) :137-154.
|
DownLoad: